| Literature DB >> 33258318 |
In Soo Kim1, Byoung Kwon Lee1, Pil Sung Yang2, Boyoung Joung3, Jong Youn Kim4.
Abstract
BACKGROUND AND OBJECTIVES: Although the adverse cardiovascular effect of anemia has been well described, the effect of polycythemia on the incident atrial fibrillation (AF) remain unclear. The objective of this study is to identify the association between increased hemoglobin and incident AF.Entities:
Keywords: Atrial fibrillation; Hemoglobins; Polycythemia; Sex
Year: 2020 PMID: 33258318 PMCID: PMC7707984 DOI: 10.4070/kcj.2020.0412
Source DB: PubMed Journal: Korean Circ J ISSN: 1738-5520 Impact factor: 3.243
Figure 1Study cohort and included subjects from the NHIS-NSC (overall general population).
NHIS-NSC = National Health Insurance Service-National Sample Cohort.
*A total of 67,306 were excluded owing to invalid data in health examination items including baseline characteristics blood test results, and smoking and alcohol history.
Baseline characteristics of men (n=217,497) and women (n=216,772) according to Hb levels
| Variables | Hb category* | |||||
|---|---|---|---|---|---|---|
| Moderate-to-severe anemia | Mild anemia | Normal | Polycythemia | |||
| Men | 1,095 | 8,726 | 185,978 | 21,698 | ||
| Hb (g/dL) | 9.7±1.3 | 12.3±0.5 | 14.9±0.9 | 17.0±0.5 | ||
| Total follow-up (years) | 3.3±1.4 | 3.8±1.3 | 3.9±1.2 | 3.8±1.3 | ||
| Age (years) | 62.9±13.8 | 59.7±14.3 | 46.5±13.8 | 42.0±12.2 | ||
| BMI (kg/m2) | 22.3±3.2 | 22.9±3.1 | 24.2±3.1 | 25.3±3.3 | ||
| Obesity (BMI ≥27.5 kg/m2) | 50 (4.6) | 628 (7.2) | 22,875 (12.3) | 4,665 (21.5) | ||
| Smoking (pack-years) | 13.4±17.9 | 14.1±17.9 | 11.6±14.3 | 12.0±13.5 | ||
| ≥20 pack-years | 341 (31.1) | 2,906 (33.3) | 47,238 (25.4) | 5,555 (25.6) | ||
| Alcohol intake (g/week) | 62.6±142.0 | 81.6±163.8 | 106.7±156.5 | 125.0±163.1 | ||
| ≥220.5 g/week | 92 (8.4) | 960 (11.0) | 26,409 (14.2) | 3,797 (17.5) | ||
| Socioeconomic status, higher† | 641 (58.5) | 5,105 (58.5) | 115,864 (62.3) | 13,583 (62.6) | ||
| CHA2DS2-VASc score | 2.0±1.8 | 1.6±1.7 | 0.6±1.0 | 0.4±0.8 | ||
| Heart failure | 113 (10.3) | 550 (6.3) | 3,348 (1.8) | 260 (1.2) | ||
| Hypertension | 592 (54.1) | 3,839 (44.0) | 37,940 (20.4) | 3,363 (15.5) | ||
| Diabetes | 249 (22.7) | 1,571 (18.0) | 12,089 (6.5) | 1,063 (4.9) | ||
| Previous ischemic stroke/TIA | 159 (14.5) | 916 (10.5) | 5,951 (3.2) | 477 (2.2) | ||
| Previous MI | 53 (4.8) | 288 (3.3) | 2,046 (1.1) | 174 (0.8) | ||
| Dyslipidemia | 402 (36.7) | 2,766 (31.7) | 32,918 (17.7) | 3,320 (15.3) | ||
| CKD | 325 (29.7) | 1,326 (15.2) | 9,485 (5.1) | 868 (4.0) | ||
| Chronic lung disease | 74 (6.8) | 576 (6.6) | 9,299 (5.0) | 282 (1.3) | ||
| Malignant diseases | 280 (25.6) | 1,353 (15.5) | 11,717 (6.3) | 933 (4.3) | ||
| Medications at enrollment | ||||||
| Antiplatelet agent | 323 (29.5) | 2,059 (23.6) | 17,482 (9.4) | 1,389 (6.4) | ||
| Oral anticoagulants | 1 (0.1) | 14 (0.2) | 186 (0.1) | 8 (0.0) | ||
| Beta-blocker | 235 (21.5) | 1,353 (15.5) | 12,647 (6.8) | 1,128 (5.2) | ||
| Statin | 182 (16.6) | 1,291 (14.8) | 13,204 (7.1) | 1,107 (5.1) | ||
| Women | 13,476 | 26,302 | 176,550 | 444 | ||
| Hb (g/dL) | 9.9±1.0 | 11.5±0.3 | 13.2±0.8 | 16.5±0.9 | ||
| Total follow-up (years) | 3.7±1.3 | 3.8±1.2 | 3.8±1.3 | 3.7±1.3 | ||
| Age (years) | 48.8±14.9 | 50.1±15.4 | 48.6±14.6 | 53.3±13.5 | ||
| BMI (kg/m2) | 22.7±3.3 | 22.8±3.2 | 23.3±3.5 | 24.9±3.9 | ||
| Obesity (BMI ≥27.5 kg/m2) | 1,075 (8.0) | 2,157 (8.2) | 19,421 (11.0) | 102 (23.0) | ||
| Smoking (pack-years) | 0.2±1.8 | 0.3±2.1 | 0.4±2.6 | 1.2±5.1 | ||
| ≥20 pack-years | 40 (0.3) | 79 (0.3) | 883 (0.5) | 11 (2.4) | ||
| Alcohol intake (g/week) | 14.1±52.9 | 14.7±52.6 | 19.2±58.4 | 26.5±76.4 | ||
| ≥220.5 g/week | 117 (0.9) | 239 (0.9) | 2,466 (1.4) | 14 (3.1) | ||
| Socioeconomic status, higher† | 7,976 (59.2) | 15,402 (58.6) | 104,200 (59.0) | 238 (53.6) | ||
| CHA2DS2-VASc score | 1.7±1.4 | 1.8±1.4 | 1.6±1.1 | 2.0±1.4 | ||
| Heart failure | 578 (4.3) | 971 (3.7) | 4,942 (2.8) | 27 (6.0) | ||
| Hypertension | 2,892 (21.5) | 6,449 (24.5) | 40,075 (22.7) | 173 (39.0) | ||
| Diabetes | 995 (7.4) | 1,823 (6.9) | 9,703 (5.5) | 54 (12.2) | ||
| Previous ischemic stroke/TIA | 656 (5.0) | 1,370 (5.2) | 7,027 (4.0) | 30 (6.7) | ||
| Previous MI | 160 (1.2) | 297 (1.1) | 1,218 (0.7) | 7 (1.5) | ||
| Dyslipidemia | 2,415 (17.9) | 5,705 (21.7) | 37,411 (21.2) | 147 (33.0) | ||
| CKD | 1,404 (10.4) | 2,233 (8.5) | 10,099 (5.7) | 49 (11.1) | ||
| Chronic lung disease | 319 (2.4) | 757 (2.9) | 4,255 (2.4) | 19 (4.4) | ||
| Malignant diseases | 954 (7.1) | 1,964 (7.5) | 11,952 (6.8) | 43 (9.7) | ||
| Medications at enrollment | ||||||
| Antiplatelet agent | 1,383 (10.3) | 2,971 (11.3) | 17,726 (10.0) | 75 (16.8) | ||
| Oral anticoagulants | 5 (0.0) | 15 (0.1) | 97 (0.1) | 1 (0.1) | ||
| Beta-blocker | 1,070 (8.0) | 2,287 (8.7) | 14,648 (8.3) | 70 (15.8) | ||
| Statin | 1,048 (7.8) | 2,656 (10.1) | 17,083 (9.7) | 77 (17.3) | ||
Values are expressed as mean±standard deviation or number (%).
BMI = body mass index; CKD = chronic kidney disease; Hb = hemoglobin; MI = myocardial infarction; TIA = transient ischemic attack.
*Baseline Hb levels of included subjects were categorized as followings based on World Health Organization statement (moderate-to-severe anemia: Hb <11.0 g/dL for both sexes; mild anemia: ≥11.0 and <13.0 g/dL for men and ≥11.0 and <12.0 g/dL for women; normal: ≥13.0 and <16.5 g/dL for men and ≥12.0 and <16.0 g/dL for women; and polycythemia: Hb ≥16.5 g/dL for men and Hb ≥16.0 g/dL for women).20) †In our cohort, socioeconomic status was divided into 11 categories (0–10) and was applied in main analysis. In this table, socioeconomic status was divided into 2 groups: higher (6–10 categories of income level) and lower (0–5 categories of income level).
Event rates and corresponding adjusted HRs for incident AF in relation to Hb levels in men and women
| Variables | Hb category | ||||
|---|---|---|---|---|---|
| Moderate-to-severe anemia | Mild anemia | Normal (Ref.) | Polycythemia | ||
| Men | 1,095 | 8,726 | 185,978 | 21,698 | |
| No. of events | 38 | 193 | 1,642 | 190 | |
| Age-standardized rate* | 394 (191–652) | 337 (278–403) | 193 (184–203) | 302 (275–333) | |
| Adjusted HR (95% CI)† | 1.70 (1.27–2.29), p<0.001 | 1.13 (0.97–1.31), p>0.05 | 1.00 (Ref.) | 1.50 (1.28–1.76), p<0.001 | |
| Women | 13,476 | 26,302 | 176,550 | 444 | |
| No. of events | 85 | 169 | 1,097 | 9 | |
| Age-standardized rate* | 144 (115–178) | 141 (121–164) | 139 (131–148) | 439 (201–833) | |
| Adjusted HR (95% CI)† | 1.26 (1.04–1.54), p<0.001 | 0.97 (0.83–1.13), p>0.05 | 1.00 (Ref.) | 1.69 (1.13–2.56), p<0.001 | |
AF = atrial fibrillation; CI = confidence interval; Hb = hemoglobin; HR = hazard ratio.
*Age-standardized rate: events per 100,000 person-years (age standardization was stratified by 5-year interval). †Age and clinical variables (including body mass index, socioeconomic status, smoking and alcohol history, baseline creatinine, and history of hypertension, diabetes, and dyslipidemia)–adjusted HR.
Figure 2Concentration-responsive U-shaped relationships between Hb level and incident AF tested by log-linear model with a thin-plate spline (age, body mass index, serum creatinine, history of hypertension, diabetes, and dyslipidemia, socioeconomic status, and smoking and alcohol intake habits-adjusted HRs). It also showed the specific Hb level (lower 95% CI more than 1.0 of HR) associated with increased risk of incident AF in both sexes.
AF = atrial fibrillation; CI = confidence interval; Hb = hemoglobin; HR = hazard ratio.
Figure 3(A) ROC curves of specific Hb level for predicting incident AF among normal Hb and polycythemia subjects (among female subjects with Hb ≥13.9 g/dL and male subjects with Hb ≥15.2 g/dL who had linearly increasing relationships between Hb and incident AF as they were shown in Figure 2). The c-indices on the basis of the AUC for Hb in predicting incident AF were 0.82 and 0.83 in women and men, respectively. Hb levels above 14.5 g/dL in women and above 16.0 g/dL in men showed the highest Youden's index (sensitivity + specificity - 1). (B and C) Kaplan-Meier curves (B, women; C, men) about the time-dependent incident AF cases according to Hb cutoff (≥14.5 g/dL in women and ≥16.0 g/dL in men) among these subjects (all long-rank p<0.05).
AF = atrial fibrillation; AUC = area of receiver operating characteristic curve; Hb = hemoglobin; ROC = receiver operating characteristics curve.
Subgroup analysis of incident AF and corresponding adjusted HRs in relation to Hb levels in men and women
| Variables | Adjusted HR* (95% CI) | |||||
|---|---|---|---|---|---|---|
| According to Hb category | With 1 g/dL increase of Hb among normal and polycythemia group | |||||
| Moderate-to-severe anemia | Mild anemia | Normal (Ref.) | Polycythemia | |||
| Men | 1.12 (1.07–1.17) ‡p<0.001 | |||||
| Age ≥65 years | 1.50 (1.17–1.93) | 1.00 (Ref.) | 1.52 (1.26–1.83) | 1.14 (1.07–1.21) ‡p<0.001 | ||
| Age <65 years | 1.22 (0.84–1.78) | 0.99 (0.83–1.18) | 1.00 (Ref.) | 1.44 (1.07–1.93) | 1.10 (1.02–1.17) ‡p=0.010 | |
| BMI <18.5 kg/m2 | 1.26 (0.49–3.26) | 0.98 (0.56–1.72) | 1.00 (Ref.) | 2.08 (1.39–3.49) | 1.25 (0.93–1.68) | |
| BMI, 18.5–22.9 kg/m2 | 0.80 (0.11–5.74) | 0.93 (0.73–1.18) | 1.00 (Ref.) | 1.33 (0.95–1.86) | 1.08 (0.99–1.19) | |
| BMI, 23.0–27.4 kg/m2 | 1.68 (1.03–2.72) | 1.18 (0.94–1.48) | 1.00 (Ref.) | 1.51 (1.05–2.17) | 1.12 (1.06–1.20) ‡p<0.001 | |
| BMI ≥27.5 kg/m2 | 1.75 (1.15–2.67) | 1.79 (1.17–2.74) | 1.00 (Ref.) | 1.52 (1.23–1.87) | 1.15 (1.03–1.29) ‡p=0.011 | |
| Smoking ≥20 pack-years | 1.81 (1.09–3.01) | 1.22 (1.02–1.46) | 1.00 (Ref.) | 1.69 (1.34–2.15) | 1.12 (1.04–1.20) ‡p=0.003 | |
| Non-smoker or smoking <20 pack-years | 1.68 (1.17–2.42) | 0.98 (0.76–1.27) | 1.00 (Ref.) | 1.38 (1.12–1.71) | 1.12 (1.06–1.19) ‡p<0.001 | |
| Lower socioeconomic status | 1.72 (1.19–2.47) | 1.18 (0.93–1.49) | 1.00 (Ref.) | 1.61 (1.33–1.94) | 1.14 (1.07–1.20) ‡p<0.001 | |
| Higher socioeconomic status | 1.70 (1.03–2.82) | 1.11 (0.92–1.34) | 1.00 (Ref.) | 1.32 (0.99–1.74) | 1.09 (1.01–1.18) ‡p=0.025 | |
| Hypertension (+) | 1.86 (1.07–3.23) | 1.23 (1.03–1.47) | 1.00 (Ref.) | 1.13 (1.06–1.20) ‡p<0.001 | ||
| Hypertension (−) | 1.67 (1.18–2.37) | 0.98 (0.75–1.29) | 1.00 (Ref.) | 1.27 (1.07–1.46) | 1.10 (1.03–1.18) ‡p=0.004 | |
| Diabetes (+) | 2.20 (1.32–3.66) | 1.20 (0.89–1.61) | 1.00 (Ref.) | 1.50 (1.27–1.78) | 1.13 (1.07–1.19) ‡p<0.001 | |
| Diabetes (−) | 1.58 (1.09–2.28) | 1.13 (0.95–1.33) | 1.00 (Ref.) | 1.49 (0.98–2.32) | 1.06 (0.94–1.19) | |
| Women | 1.18 (1.10–1.26) ‡p<0.001 | |||||
| Age ≥65 years | 1.29 (1.01–1.64) | 1.01 (0.78–1.29) | 1.00 (Ref.) | 3.26 (1.45–7.29) | 1.22 (1.10–1.35) ‡p<0.001 | |
| Age <65 years | 1.25 (0.93–1.80) | 0.97 (0.80–1.17) | 1.00 (Ref.) | 0.42 (0.06–2.98) | 1.15 (1.05–1.26) ‡p=0.003 | |
| BMI <18.5 kg/m2 | 1.30 (0.63–2.68) | 1.08 (0.85–1.38) | 1.00 (Ref.) | 4.44 (0.12–14.25) | 1.56 (1.07–2.26) ‡p=0.020 | |
| BMI, 18.5–22.9 kg/m2 | 0.95 (0.50–1.80) | 0.63 (0.28–1.46) | 1.00 (Ref.) | 0.87 (0.12–6.20) | 1.13 (0.99–1.29) | |
| BMI, 23.0–27.4 kg/m2 | 1.15 (0.84–1.59) | 0.90 (0.71–1.14) | 1.00 (Ref.) | 1.92 (0.72–5.14) | 1.12 (1.02–1.24) ‡p=0.021 | |
| BMI ≥27.5 kg/m2 | 1.39 (1.04–1.86) | 1.01 (0.67–1.49) | 1.00 (Ref.) | 2.69 (0.67–10.81) | 1.34 (1.16–1.55) ‡p<0.001 | |
| Smoking ≥20 pack–years | 1.27 (1.04–1.54) | 2.98 (1.02–8.75) | 1.00 (Ref.) | 1.87 (1.17–3.12) | 1.19 (1.11–1.27) ‡p<0.001 | |
| Non-smoker or smoking <20 pack-years | 1.11 (0.11–11.14) | 0.96 (0.82–1.12) | 1.00 (Ref.) | 1.62 (0.67–3.43) | 0.76 (0.42–1.40) | |
| Lower socioeconomic status | 1.28 (0.95–1.73) | 1.09 (0.90–1.32) | 1.00 (Ref.) | 2.12 (1.29–3.70) | 1.19 (1.09–1.30) ‡p<0.001 | |
| Higher socioeconomic status | 1.25 (0.97–1.61) | 0.82 (0.63–1.05) | 1.00 (Ref.) | 1.35 (0.43–4.18) | 1.17 (1.06–1.30) ‡p=0.003 | |
| Hypertension (+) | 1.40 (1.11–1.76) | 1.02 (0.85–1.23) | 1.00 (Ref.) | 2.73 (1.08–5.51) | 1.19 (1.06–1.34) ‡p=0.003 | |
| Hypertension (−) | 1.10 (0.77–1.58) | 0.90 (0.69–1.18) | 1.00 (Ref.) | 1.30 (0.49–3.48) | 1.17 (1.08–1.27) ‡p<0.001 | |
| Diabetes (+) | 1.31 (1.05–1.62) | 0.99 (0.83–1.17) | 1.00 (Ref.) | 2.11 (1.01–4.45) | 1.18 (1.10–1.27) ‡p<0.001 | |
| Diabetes (−) | 1.15 (0.75–1.76) | 0.93 (0.65–1.33) | 1.00 (Ref.) | 1.53 (0.41–7.08) | 1.17 (1.01–1.38) ‡p=0.049 | |
Bold-faced p values are <0.05 compared to normal Hb group.
AF = atrial fibrillation; BMI = body mass index; CI = confidence interval; Hb = hemoglobin; HR = hazard ratio.
*Age and clinical variables (including BMI, socioeconomic status, smoking and alcohol history, baseline creatinine, and history of hypertension, diabetes, and dyslipidemia)–adjusted HR. †Interaction p value <0.05 (compared with the opposite subgroup of each). ‡p<0.05.